---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-139510"
form_type: "8-K"
ticker: "RNTX"
cik: "0001420565"
company_name: "Rein Therapeutics, Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T22:51:06.152070+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aileron posts Q1 net loss of $7.1M; positive Phase 1b data for LTI-03 in IPF

## Summary
- Q1 net loss $7.1M ($0.86/share) vs $4.8M ($1.05) in Q1 2023; R&D expenses rose to $3.5M from $1.8M.
- Cash $12.0M at March 31, 2024; after May 2024 $20M offering, expects to fund operations into H2 2025.
- Positive Cohort 1 data for LTI-03 in IPF: statistically significant in 3 of 8 biomarkers; no SAEs reported.
- Topline results from high-dose Cohort 2 expected Q3 2024; also Brian Windsor appointed President and CEO in March.

## SEC filing metadata
- accession: 0001193125-24-139510
- form_type: 8-K
- ticker: RNTX
- cik: 0001420565
- company_name: Rein Therapeutics, Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420565/000119312524139510/0001193125-24-139510-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420565/000119312524139510/d825172d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-139510
- JSON: https://secwatch.observer/filing/0001193125-24-139510.json
- Plain text: https://secwatch.observer/filing/0001193125-24-139510.txt

## Key facts
- Earnings Releases
  Rein Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income Net loss for the quarter ended March 31, 2024, was $7.1 million, compared to $4.8 million for the corresponding quarter, EPS The basic and diluted net loss per share for the quarter ended March 31, 2024 was $0.86 compared to $1.05 for the quarte.
  - Period: first quarter ended March 31, 2024
  - Net income: Net loss for the quarter ended March 31, 2024, was $7.1 million, compared to $4.8 million for the corresponding quarter
  - EPS: The basic and diluted net loss per share for the quarter ended March 31, 2024 was $0.86 compared to $1.05 for the quarte
  - Result: reported results
  source text: Net loss for the quarter ended March 31, 2024, was $7.1 million, compared to $4.8 million for the corresponding quarter in 2023. The basic and diluted net loss per share for the quarter ended March 31, 2024 was $0.86 compared to $1.05 for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1420565/000119312524139510/0001193125-24-139510-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.